Nyandwi Joseph, Bazikamwe Sylvestre, Nisubire Désiré, Ndabashinze Pontien, Shaker Mohamed Elsayed, Said Eman
Hemodialysis Unit, Department of Internal Medicine, University Hospital of Kamenge, Bujumbura, Burundi.
Department of Gynecology and Obstetrics, University Hospital of Kamenge, Bujumbura, Burundi.
East Afr Health Res J. 2018;2(2):112-117. doi: 10.24248/EAHRJ-D-18-00003. Epub 2018 Nov 23.
Prevention of mother-to-child transmission (PMTCT) programmes aim to both eliminate vertical transmission of HIV and optimise the health and survival of infants born with HIV. Therefore, early infant diagnosis (EID) of HIV infection via DNA polymerase chain reaction (PCR) testing is a key component of PMTCT programming. We assessed the effectiveness of EID and PMTCT interventions at health-care facilities in Bujumbura, Burundi.
This was a prospective analytical study of infants born to HIV-positive mothers on antiretroviral therapy (ART), who were followed from December 2016 to March 2017 at 3 centres providing PMTCT services in Bujumbura. Babies enrolled in this study received once-daily nevirapine from birth through to 6 weeks of life, after which HIV DNA PCR testing was conducted.
Of 122 HIV-exposed infants, 60 were boys and 62 were girls. The mother-to-child transmission rate at 6 weeks of life was 0.9%. Eighty-three (68%) of the women had commenced ART before pregnancy and 39 (32%) during pregnancy. The mean CD4 lymphocyte count was 653±308 cells/μl. Ninety-two (75.4%) of the pregnancies were planned, and 98 (80%) of the births were via spontaneous vaginal delivery. After birth, 111 (91.0%) infants were exclusively breastfed, and 11 (9.0%) infants received exclusive replacement feeding.
There was a low rate of transmission of HIV from women taking ART to children who were given nevirapine for the first 6 weeks of life. Infants of HIV-positive women can live healthy lives free from HIV infection if their mothers participate in PMTCT programmes.
预防母婴传播(PMTCT)项目旨在消除艾滋病毒的垂直传播,并优化感染艾滋病毒婴儿的健康和生存状况。因此,通过DNA聚合酶链反应(PCR)检测对婴儿进行早期艾滋病毒诊断(EID)是PMTCT项目的关键组成部分。我们评估了布隆迪布琼布拉医疗机构中EID和PMTCT干预措施的有效性。
这是一项对接受抗逆转录病毒治疗(ART)的艾滋病毒阳性母亲所生婴儿进行的前瞻性分析研究,于2016年12月至2017年3月在布琼布拉提供PMTCT服务的3个中心对这些婴儿进行随访。参与本研究的婴儿从出生到6周龄每天接受一次奈韦拉平治疗,之后进行艾滋病毒DNA PCR检测。
在122名暴露于艾滋病毒的婴儿中,60名是男孩,62名是女孩。6周龄时的母婴传播率为0.9%。83名(68%)妇女在怀孕前开始接受ART治疗,39名(32%)在怀孕期间开始治疗。平均CD4淋巴细胞计数为653±308个/μl。92例(75.4%)妊娠是计划内的,98例(80%)分娩是自然阴道分娩。出生后,111名(91.0%)婴儿纯母乳喂养,11名(9.0%)婴儿接受纯替代喂养。
接受ART治疗的妇女将艾滋病毒传播给在生命最初6周接受奈韦拉平治疗的儿童的比率较低。如果艾滋病毒阳性妇女的母亲参与PMTCT项目,她们的婴儿可以健康生活,免受艾滋病毒感染。